1. 179P Early proof of concept of safety and clinical activity of clonal neoantigen-reactive T cells (cNeT). (December 2022) Authors: Forster, M.D.; Cave, J.; Greystoke, A.; Plummer, R.; Spicer, J.; Thistlethwaite, F.; Turajlic, S.; Craig, A.; Newton, K.; Saggese, M.; Quezada, S.; Peggs, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience. (December 2022) Authors: Zhang, S.H.; Cartwright, E.; Mullings, S.; Ferro Lopez, L.F.; Cunningham, D.; Chau, I.; Starling, N.; Popat, S.; O'Brien, M.E.R.; Bhosle, J.; Minchom, A.R.; Davidson, M.; Tokaca, N.; Lalondrelle, S.; Pickering, L.M.; Furness, A.; Turajlic, S.; Larkin, J.; José, R.; Young, K. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma. (6th March 2016) Authors: Spain, L.; Higgins, R.; Gopalakrishnan, K.; Turajlic, S.; Gore, M.; Larkin, J. Journal: Annals of oncology Issue: Volume 27:Number 6(2016:Jun.) Page Start: 1135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution. (1st March 2021) Authors: Edwards, C. L.; Comito, F.; Agraso Busto, S.; Harland, C.; Turajlic, S.; Larkin, J.; Heelan, K.; Fearfield, L. Journal: Clinical and experimental dermatology Issue: Volume 46:Number 2(2021) Page Start: 338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution. (22nd October 2020) Authors: Edwards, C. L.; Comito, F.; Agraso Busto, S.; Harland, C.; Turajlic, S.; Larkin, J.; Heelan, K.; Fearfield, L. Journal: Clinical and experimental dermatology Issue: Volume 46:Number 2(2021) Page Start: 338 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Severe cutaneous adverse reaction following COVID‐19 vaccination and immunotherapy: a second hit?. (1st January 2022) Authors: Hussain, K.; Kawsar, A.; Weir, J.; Au, L.; Turajlic, S.; Larkin, J.; Fearfield, L. Journal: Clinical and experimental dermatology Issue: Volume 47:Number 1(2022) Page Start: 149 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. TCR sequencing: applications in immuno-oncology research. (March 2023) Authors: Sanromán, Á.F.; Joshi, K.; Au, L.; Chain, B.; Turajlic, S. Journal: Immuno-oncology technology Issue: Volume 17(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗